The induced pluripotent stem cell (iPSC)-derived natural killer cell therapy landscape is experiencing significant clinical advancement, with more than a dozen companies now developing over 15 pipeline candidates across multiple development stages. This expansion reflects growing industry confidence in the therapeutic potential of engineered NK cells for treating hematologic and solid malignancies, with major players including Century Therapeutics, Fate Therapeutics, and Cartherics driving the field forward through clinical validation.
Recent clinical milestones have underscored the approach's promise. Century Therapeutics continues Phase I/II evaluation of CNTY-101, while Fate Therapeutics reported encouraging early-stage data for FT522 in patients with relapsed or refractory B-cell lymphoma. These developments represent meaningful progress in translating iPSC technology into viable therapeutic options, addressing a critical need for off-the-shelf cellular immunotherapy products that can overcome limitations associated with patient-derived CAR-T cell manufacturing.
Industry observers view iPSC-derived NK cells as a potentially transformative platform for cancer immunotherapy, offering advantages including scalable manufacturing, reduced production timelines, and the ability to engineer enhanced functional properties at the outset. The convergence of multiple well-funded programs suggests the field is moving beyond early-stage validation toward more definitive clinical assessment of safety and efficacy profiles.